Skip to content

Study · Systematic review · n = 331 · 2025

2 results

Oxytocin in old age psychiatry: A systematic review of the safety of using intranasal oxytocin in older adults.

Sawares A, Olver J, Morcos M, Norman T

Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists30 Oct 2024Cited by 4 (Europe PMC)

PMID39474844 (opens in a new tab)PMCIDPMC11804147 (opens in a new tab)DOI10.1177/10398562241291335 (opens in a new tab)PepBankPUB-39474844
Read at sourcePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanSystematic reviewSafety outcome

    In older adults across nine randomized trials, adverse effects of intranasal oxytocin were mostly mild and varied inconsistently between studies.

    In plain wordsIn older adults, side effects of nasal oxytocin were mostly mild and differed between studies.

    Peptide
    Oxytocin
    Outcome
    MixedAdverse effects of intranasal oxytocin in older adults
    Study

    n = 331

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Source sentences

    Summary
    Adverse effects associated with oxytocin administration were predominantly mild and varied inconsistently between studies.
    1 context sentence
    Summary · context
    The search identified nine randomized controlled trials (RCTs) that investigated the effects of intranasal oxytocin on a total sample size of 331 older participants.
  2. 02HumanSystematic reviewSafety outcome

    In older adults, intranasal oxytocin at 24 to 72 IU was not significantly associated with severe adverse outcomes compared with placebo in the short term.

    In plain wordsIn older adults, nasal oxytocin was not linked to more severe side effects than placebo in short-term use.

    Peptide
    Oxytocin
    Outcome
    No significant changeSevere adverse outcomes versus placebo
    Study

    n = 331

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    24-72 IU · intranasal · single or repeated doses in the short termAs given in this study (human).

    Source sentences

    Summary
    Compared to placebo intranasal oxytocin was not significantly associated with severe adverse outcomes in doses ranging from 24 to 72 IU after single dose and or repeated doses in the short-term.
    1 context sentence
    Summary · context
    The search identified nine randomized controlled trials (RCTs) that investigated the effects of intranasal oxytocin on a total sample size of 331 older participants.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2NCT06945926

The Effect of Oxytocin Nasal Spray on Preventing Postoperative Delirium in Elderly Patients Undergoing Orthopedic Surgery

Zhejiang Universityn = 2271 Jun 2025 to 2 Jun 2026

Cervical Spinal Stenosis · Thoracic Spinal Stenosis · Lumbar Spinal Stenosis · Rotator Cuff Injury · Femoral Head Necrosis · Spinal Trauma · Knee Joint Injury

Trial pageClinicalTrials.govUpdated 20 Aug 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.